Morgan Stanley analyst Kristine Liwag lowered the firm’s price target on Northrop Grumman (NOC) to $745 from $765 and keeps an Overweight rating on the shares. Shares sold off post-print as the magnitude of B-21 investments “took investors by surprise,” but the firm remains bullish on the long-term outlook, the analyst says in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOC:
- Northrop Grumman Earnings Call Highlights Growth Ramp
- Balanced Risk‑Reward as Long‑Term Program Upside Offsets Near‑Term Free Cash Flow Constraints at Northrop Grumman
- Northrop Grumman files automatic mixed securities shelf
- Northrop Grumman: Expanding annual production capacity on B-21 aircraft by 25%
- Northrop Grumman raises FY26 CapEx view to $1.85B from $1.65B